Trending Topic

Low poly brain or Artificial intelligence concept. Symbol of Wisdom point. Abstract vector image of a human Brain. Low Polygonal wireframe blue illustration on dark background. Lines and dots.
21 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may signify serious malfunction of, or damage to, the immature brain and […]

Susan Hutchinson, AAN 2021: Rimegepant for the Prevention and Treatment of Migraine

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 23rd 2021

It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine.

The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.

Questions:

  1. What are the unmet needs in the treatment of migraine in adults with cardiovascular risk factors? (0:13)
  2. Could you give us a brief overview of the clinical development of small molecule CGRP receptor antagonists for migraine prevention and treatment? (1:01)
  3. Could you please describe your recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors? (1:40)
  4. What were the findings of this study and what are their implications for clinical practice? (3:32)
  5. What does the future migraine treatment landscape look like? (4:46)

Disclosures: In the past two years, Susan Hutchinson has served as a consultant/advisory board member for Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith; and is on the speaker’s bureau for AbbVie, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica and Upsher-Smith.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AAN Annual Virtual Meeting 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup